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1. Introduction 
1.1 General aspects of Sjögren’s syndrome  
1.1.1 Definition 
Sjögren’s syndrome (SS) is a chronic autoimmune disease associated with the production of 
autoantibodies and characterized by a progressive lymphocytic and plasma cell infiltration 
of the salivary and lacrimal glands leading to xerostomia and keratoconjunctivitis sicca (1). 
A Danish ophthalmologist named Henrik Sjögren in 1932 was the first one, who reported 
the triad of keratoconjunctivitis sicca, xerostomia, and rheumatoid arthritis and then Sjögren 
introduced the term keratoconjunctivitis sicca for this syndrome, to distinguish it from dry 
eyes caused by lack of vitamin A (2). It is characterized by lymphocytic infiltration and 
subsequent destruction of the exocrine glands (3–5) including those found in the nose, ears, 
skin, vagina, respiratory and gastrointestinal systems (6).  
1.2 Diagnosis 
1.2.1 Differential diagnosis 
The diagnosis of SS is not straightforward as many of the symptoms are subjective (Figure 1) (5).  
 
Fig. 1. Differential Diagnosis of SS (5) 
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1.2.2 Diagnostic criteria 
The criteria for diagnosis of SS remain controversial, and different diagnostic criteria have 
been proposed. The syndrome can present primary or secondary. Generally, SS is classified 
as secondary (SS-2) when it is associated with other autoimmune diseases such as 
rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis and 
polymyositis and as primary (SS-1) when there is no other connective tissue disease (7, 8). 
There are at least 6 international diagnostic criteria, such as Fox criteria, San Diego criteria, 
San Francisco criteria, European criteria (EEC), American-European Consensus Group 
(AECG) criteria, and Copenhagen criteria. San Diego criteria requires evidence for an 
autoimmune process associated with destruction of salivary and lacrimal gland tissues 
while the Copenhagen and EEC study group have based their diagnostic criteria on clinical 
findings of dry eyes and mouth with no absolute requirement for gland biopsy or presence 
of autoantibodies.  
On the other hand, Sjögren’s Syndome Foundation (SSF) stressed that the classification 
criteria for Sjögren’s syndrome currently used by clinicians and researchers around the 
world is the American-European Consensus Classification Criteria (Table 1). Because many 
different criteria previously were used both within the U.S. and in other countries, the 
Sjögren’s Syndrome Foundation and members of the European Study Group on 
Classification Criteria brought international leaders in Sjögren’s together to develop 
consensus on one set of guidelines (9). SSF mentioned that that classification criteria is the 
strictest criteria available to prove a definitive diagnosis of Sjögren’s for research purposes. 
Physicians usually diagnose SS for clinical purposes on a more individual, medically 
intuitive and broader basis. However, none of them was approved by the World Health 
Organization, which suggested better diagnostic criteria should be established.  
1.3 Prevalance 
Sjögren’s syndrome occurs worldwide and in all ages. The peak incidence is in the fourth 
and fifth decades of life, with a female : male ratio of 9:1 (13). A number of studies have 
shown great variation in the frequency of Sjögren’s syndrome (14). Prevalence studies have 
demonstrated that sicca symptoms and primary Sjögren’s syndrome affects a considerable 
percentage of the population, with precise numbers dependent on the age group studied 
and on the criteria used (15). A cautious but realistic estimate from the studies presented 
thus far is that primary Sjögren’s syndrome is a disease with a prevalence not exceeding 
0.6% of the general population (15). 
1.4 Aetiology and pathogenesis 
The etiology of Sjogren’s syndrome remains unidentified (16). Interactions between 
environmental contributors such as viruses or stress in conjunction with genetic 
susceptibility factors and hormonal effects are currently believed to result in disease 
development (16, 17). Intrinsic activation of epithelium in various target organs was 
demonstrated (18), based on inappropriate expression of MHC molecules, overexpression of 
costimulatory molecules and capacity for cytokine production, and the term “autoimmune 
epithelitis” was proposed (19). In the context of SS, Epstein Barr, HTLV-1, Hepatitis-C and 
enteroviruses have been previously proposed as potential initiating factors of the SS 
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I. Ocular Symptoms (at least one) 
- Dry eyes >3 months? 
- Foreign body sensation in the eyes? 
- Use of artificial tears >3x per day? 
II. Oral Symptoms (at least one) 
- Dry mouth >3 months? 
- Recurrent or persistently swollen salivary glands? 
- Need liquids to swallow dry foods? 
III. Ocular Signs (at least one) 
- Schirmer's test, (without anesthesia) ≤5 mm/5 minutes 
- Positive vital dye staining (van Bijsterveld ≥4) 
IV. Histopathology Lip biopsy showing focal lymphocytic sialoadenitis 
- focus score ≥1 per 4 mm2)2 
V. Oral Signs (at least one) 
- Unstimulated whole salivary flow (≤1.5 mL in 15 minutes) 
- Abnormal parotid sialography3 
- Abnormal salivary scintigraphy4 
VI. Autoantibodies (at least one) 
- Anti-SSA (Ro) or Anti-SSB (La) 
For a primary Sjögren’s syndrome diagnosis: 
a. Any 4 of the 6 criteria, must include either item IV (Histopathology) or VI 
(Autoantibodies) 
b. Any 3 of the 4 objective criteria (III, IV, V, VI) 
For a secondary Sjögren’s syndrome diagnosis: 
In patients with another well-defined major connective tissue disease, the presence of one 
symptom (I or II) plus 2 of the 3 objective criteria (III, IV and V) is indicative of secondary 
SS. 
Exclusion Criteria 
Past head and neck radiation treatment 
Hepatitis C infection 
Acquired immunodeficiency syndrome (AIDS) 
Pre-existing lymphoma 
Sarcoidosis 
Graft versus host disease 
Current use of anticholinergic drugs 
 
Table 1. American-European Consensus Classification Criteria accepted by Sjögren’s 
Syndome Foundation (9-12) 
(16, 20) However, the mechanisms that account for the epithelial activation remain stil 
unclear (16). Recent data suggest the central role of the type I interferon (IFN) system in the 
pathogenesis of many autoimmune disorders including SS (16).  
A genetic predisposition to SS has been suggested because of multiple reports of two or 
more members of the same family developing the syndrome (21). A family history of the 
disease puts people at an increased risk of developing SS compared to the general 
population (22). This is also supported by the development of SS in twins (22). A genetic 
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susceptibility may be required for the development of autoantibodies which are found in SS 
(22) and this may be associated with a link between polymorphic major histocompatibility 
complex (MHC) genes and the development of autoimmune diseases (21).  
High cDNAlevels in patients with SS may result with a disease at worst prognosis which 
should the clinician let to follow-up the patients with SS both, clinically and serologicallly 
(23). The study of Alevizos et al. revealed that microRNA are promising candidate 
biomarkers of inflammation and salivary gland dysfunction in patients with SS (24). Further 
exploration of the predicted pathways associated with decreased salivary flow in this study 
will provide insight into the pathophysiology of SS and may identify novel therapeutic 
targets (24-25). 
1.5 Complications 
SS systemic disease may affect many other body systems. The most serious complication of 
SS could be accepted as the increased incidence of malignant lymphoma (26). This 
fhenemenon was first reported in patients with SS in 1963 (26) and has been shown to be 44 
times higher than the general population in some studies (27). Additionally, multiple case 
reports supported the association of lymphoma with Sjögren syndrome and stressed 
lymphoma as the major complication in the progression of the disease (28, 29). When it 
occurs, patients with SS are accepted as they are in stage 3 who consist of %5 of the general 
SS population.  
Severeal studies have shown different involvements in patients with SS such as 
hematological system, respiratory system, cardiac, liver, pancreatic, renal, thyroid and 
finally exocrine glands involvements. Bayetto and Logan have summerized extraglandular 
manifestations of SS in a table perfectly (Table 2) (27, 57). 
 
Malaise Peripheral neuropathy Primary biliary cirrhosis 
Fatigue Autoimmune thyroiditis GI symptoms 
Fibromyalgia Renal tubular acidosis Respiratory diseases 
Fever Myositis Psychosis 
Arthralgia Chronic hepatitis Lymphadenopathy 
Synovitis Purpura Splenomegaly 
Raynaud’s phenomenon Vasculitis Lymphoma 
Table 2. Symptoms associated with extraglandular manifestations of Sjögren’s syndrome by 
(27, 57) 
Briefly, leucopenia (approximately 45% of all SS cases), thromboycytopenia (approximately 
25% of all SS cases), hemolytic anemia (approximately 5% of all SS cases) and lower 
thrombopoietin levels (approximately 20% of all SS cases) are accepted as hematological 
system involvement of the disease. Respiratory system involvement of the disease reveals 
interstitial lung disease (approximately 20% of all SS cases), pulmonary hypertension 
(approximately 12% of all SS cases) and multiple nodules (approximately 5% of all SS cases). 
pericardial effusion (approximately 15% of all SS cases) and atrioventricular conduction 
block (approximately 5% of all SS cases) are the cardiac complications of the disease. The 
liver damage could be seen almost one third of the patients with SS. Likewise approximately 
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one third of the patients with SS revealed hepatosplenomegaly. Elevated gamma-glutamyl 
transpeptidase, alaine transferase and alkaline phosphatase levels are seen approximately in 
one fifth of the patients with SS. Renal involvement in SS are relatively common. Proteinuria 
(approximately 20% of all SS cases), Renal tubular acidosis (approximately 15% of all SS 
cases) and kidney stones and/or renal calcification (approximately 10% of all SS cases) are 
the most important renal complications of the disease. Thyroid disorders are also common 
among the patients with SS (33% of all cases). Abnormal thyroid function was seen in one 
forfth of the whole SS population (30). 
1.6 Pediatric cases 
SS is very rare in childhood and is frequently undiagnosed (31). Literature search revealed 
200 pediatric cases of SS. The most important clinical manifestations in children with SS is 
the recurrent parotid swelling (31). Pathologic and laboratory findings are similar to those 
found in adults, with characteristic lymphocytic infiltration of exocrine glands, the presence 
of hypergammaglobulinemia, elevated erythrocyte sedimentation rate, and positive anti–SS 
antigen A, anti–SS antigen B, antinuclear antibody, and rheumatoid factor (32-34). 
Inflammation characterized by recurrent episodes of painful unilateral or bilateral parotid 
enlargement associated with swelling, fever, redness, and reduction in salivary flow (35-39). 
1.7 Management 
Sicca symptoms of the disease could be treated by using topical agents wheras 
extraglandular features are managed with glucocorticoids and immunosuppressive drugs 
(40). But, literature search revealed no evidence based therapeutic guidelines for the 
management of primary Sjögren syndrome which is also universally accepted (41). The 
results of one excellent systematic review about the treatment of SS shows that B cell 
targeted agents seem to be the most promising future therapy, especially rituximab, which 
has been used in more than 100 reported cases. Agents that block B cell–activating factor of 
the tumor necrosis factor family may also be a promising therapy (41, 42). Advances in 
knowledge of the molecular mechanisms involved in the etiopathogenesis of Sjögren’s 
syndrome may allow the development of more effective, highly selective therapies without 
the adverse effects often associated with standard, less-selective drugs (41). Today, current 
treatment options are decided upon a mix of personal experience, expert opinion, and 
reported studies (41). 
2. Oral aspects of Sjögren’s syndrome 
2.1 Saliva, glandular involvement, xerostomia and treatment 
2.1.1 Saliva  
Saliva is secreted from three major paired glands which are parotid, submandibular and 
sublingual glands and from hundreds of minor salivary glands which are localized over most 
parts of the oral mucosa (43). About 90% of mixed saliva is derived from three pairs of major 
salivary glands (parotid, submandibular and sublingual) and the remaining 10% is from 
numerous minor salivary glands distributed in the oral mucosa (43). In healthy humans, the 
daily production of whole saliva (mixed saliva) normally ranges from 0Æ5 to 1Æ5 L (43).  
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The salivary secretion is mainly induced during eating (43). Stimulated saliva which is also 
called as reflex salivation helps the chewing of food, formation and swallowing of a food 
bolus and digestion of starch and lipids (43). Saliva takes also part in the detection of food 
taste through the diffusion of taste substances to taste receptors, chemical interaction with 
taste substances and changes in the sensitivity of taste receptors (43). On the other hand, 
resting saliva, which is a lesser amount of saliva, covers the surface of the oral and 
pharyngeal cavities (43). When compared to the stimulated saliva resting saliva is accapted 
as more important in the maintenance of oral health (43). Protection properties against 
bacteria ⁄ - viruses ⁄ fungi are based on the salivary anti-microbial action [such as lysozyme, 
peroxidase, secretory immunoglobulin A (IgA) and histatins] and also on adhesion (mucins) 
and rinsing properties (43). Saliva is also responsible by taking part in speech, denture 
holding, anticaries activity, controlling breath odour and maintaining the integrity of oral 
and gastrointestinal mucosa (43). 
Acinar cells produce saliva at first (43). Two types of these cells have been detected: serous 
and mucous cells (43). The parotid gland has serous acinar cells and secretes a thin, watery 
and amylase-rich saliva through its main excretory duct which is called as Stenson ductus; it 
opens onto the buccal mucosa near the upper molar teeth (43). The submandibular gland 
produces a more viscous and mucin-rich saliva and it consists of serous and mucous acinar 
cells whereas the sublingual gland has mucous acinar cells and also produces a viscous 
mucin rich saliva (43). 
The sympathetic and parasympathetic autonomic nervous systems control mainly the 
salivary secretion (44). The sympathetic nerve is mainly responsible for the secretion of 
proteins accompanied by exocytosis in acinar cells, while the parasympathetic nerve is 
mainly responsible for the secretion of water and electrolytes (44). These are adequate 
stimuli for salivation, and secreted saliva is called stimulated saliva (43). Saliva secreted in 
the absence of apparent sensory stimuli related to eating refers to resting or unstimulated 
saliva (43). This saliva may have two components; one is spontaneous secretion, which is the 
continuous production of small amounts of saliva without any extraneous stimuli (43). 
There are prominent differences between stimulated and resting salivary secretions in their 
flow rate and viscosity (43). The flow rate of resting whole saliva is far less than that of 
stimulated whole saliva, whereas the viscosity of resting whole saliva is 2–3 times that of 
stimulated whole saliva in healthy adults which implies that resting whole saliva is rich in 
mucins mainly secreted by sublingual, submandibular and palatal glands (45). Resting 
whole saliva contains a higher concentration of high-molecular-weight mucin (MG1) than 
stimulated whole saliva, whereas low-molecular weight mucin (MG2) shows similar 
concentrations under resting and stimulated conditions (46).  
One of two main roles of saliva in taste perception is the relatively short-term effect of saliva 
seen in the initial processes of taste perception (47). Taste substances should be dissolved in 
the salivary fluid layer to reach and stimulate taste receptors (43). The solubilization of taste 
substances in saliva, the chemical interaction between taste substances and salivary 
compositions, and the diffusion and dilution of taste substances in saliva are the ones which 
are responsible (43). Additionally, some components which can also stimulate taste 
receptors and ⁄ or change taste sensitivity by chemical interaction with the receptor are 
contained in the saliva (43). One other long-term effect of saliva is maintaining the health 
and function of the taste receptor site (43). 
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2.1.2 Glandular involvement 
Garcio-Carrasco et al. summarized the mechanism of gland-induced dysfunction in primary 
SS in their excellent review article (Figure 2) (58). 
 
Fig. 2. Main mechanisms of gland-induced dysfunction in pSS. INF, interferon; MMP, 
metalloproteinase (58). 
2.1.3 Xerostomia & treatment 
Xerostomia is defined as a subjective complaint of dry mouth that may result from deficient 
production of saliva (48). Xerostomic patients complain mostly about burning mouth, loss of 
taste, difficulty in swallowing, unpleasant taste and odor, oral dryness, increased thirst, 
chewing, speaking, gastroesophageal reflux, oral breathing, malfunction of removable 
prosthesis and sensitive teeth (49-54). Allec et al. concluded in their prospective cross-
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sectional descriptive observational study that patients with SS have voice, speech and 
swallowing abnormalities, not only associated with to xerosis but perhaps also to 
neurological abnormalities, probably secondary to the syndrome (55). On the other hand, 
subjective xerostomia has been reported in higher percentages (75.18% to 91.84%) in patients 
with SS (56). In addition to that, Skopouli et al. showed that the rate of dry mouth increased 
from 41% of patients at initial diagnosis to 84% 10 years after diagnosis (57). Salivary gland 
dysfunction appears due to progressing lymphocytic infiltration in salivary acini, which in 
turn leads to inflammatory reaction causing acinar atrophy and proliferation of connective 
tissue (58). Sometimes such pathological changes originate in the minor salivary glands and 
may result in early symptoms of xerostomia, which are less intense than those in cases when 
the major salivary glands are affected (48).  
Alcohol and smoking should be avoided and thorough oral hygiene is essential (40, 59). 
Saliva replacement products and sugarfree chewing gums may be effective for mild to 
moderate dry mouth (41). Oral pilocarpine and cevimeline are the treatment of choice for 
patients with SS (41). The doses that best balance efficacy and adverse effects are reported to 
be 5 mg every 6 hours for pilocarpine and 30 mg every 8 hours for cevimeline (41). In 
patients with contraindications or intolerance to muscarinic agonists, N-acetylcysteine may 
be an alternative (41). 
2.2 Risk of dental caries and erosions & treatment 
2.2.1 Risk of dental caries and erosions  
The reduced salivary flow and its altered composition influence the bacterial clearance in 
the oral cavity as well as the accumulation of dental plaque on teeth surfaces (60). In 
addition to that, the saliva loses its ability to buffer, lubricate, and perform antimicrobial 
duties which leads to an increase in mucosal friability and oral infection (61). Increased 
incidence of cervical, incisal, decays in cusps tips and root caries has been reported in 
patients with SS as a major dental problem (62). These types of decays are accepted as 
atypical or unusual dental decays. This is constant demineralization, a rapidly progressing 
(rampant) and aggressive form of dental decay (43). 
Mathews et al. mentioned in their excellent review article named ‘Oral manifestations of 
Sjögren's syndrome’ that dental plaque, consisting of more than 500 species of bacteria in a 
mature state, is a complex biofilm of microbes that adheres to the surfaces of teeth and 
provides a reservoir for oral microbial pathogens (61, 63, 64). Sjögren's syndrome increases a 
person's likelihood of contracting opportunistic infections and the proliferation of cariogenic 
micro-organisms (61, 65). Pederson et al. have reported that persons with primary Sjögren's 
syndrome have lower numbers of periopathogenic microorganisms and higher numbers of 
cariogenic and acidophilic micro-organisms in comparison with those found in control 
individuals (61, 66). Pederson et al. concluded in another study that patients with a labial 
salivary gland biopsy focus score of one or more (as per the American-European 
Classification Criteria) or the presence of Ro⁄SSA and La ⁄ SSB antibodies in serum, had a 
significantly higher DMFT⁄DMFS score than patients without these two factors (67). 
Boutsi et al. mentioned in their study investigating dental and periodontal status of patients 
with SS that the number of cervical decay lesions correlated negatively with the salivary 
flow (56). It is known that because of reduced salivary flow, bacterial plaque accumulates 
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more rapidly on the tooth surface and especially at the marginal gingiva and crevicular 
areas which results in a higher prevalence of cervical caries (56). In patients with SS, an 
increased number of decayed and filled teeth surfaces have been referred previously by 
several investigators (62, 68). The very low salivary secretion rates, the decreased buffering 
effect and neutralization of bacterial acids as well as the high counts of lactobacilli and 
streptococci found in patients with SS, may be responsible for this effect (69). It is interesting 
that in their study, the number of cervical decay lesions correlated negatively with the 
salivary flow, while the number of distal or mesial decay lesions correlated negatively with 
age (56). It seems that the lack of salivary flow affects more extensively the cervical surfaces 
of the teeth, and predisposes them to a more rapid development of caries (56). 
2.2.2 Treatment 
Mese and Matsua stressed that patients should be advised to maintain impeccable hygiene, 
schedule frequent examinations and use topical fluoride regimens (43). The choice of the 
fluoride-delivery system varies with the clinical need and patient compliance (43). Common 
sources of fluoride in toothpaste are sodium monofluorophosphate and sodium fluoride (70-
72). But Mathews et al reported that even with excellent oral hygiene, individuals with 
Sjögren's syndrome have elevated levels of dental caries, along with the loss of many teeth 
early in the disease (61). Pedersen et al. reported that persons who brushed their teeth with 
toothpaste containing fluoride and visited their dentist more frequently still had higher 
numbers of missing, filled, and decayed teeth, along with a higher gingival index (66).  
2.3 Periodontal status & treatment 
2.3.1 Periodontal status 
The reduced salivary flow and its altered composition influence the bacterial clearance in 
the oral cavity, as well as the increased accumulation of dental plaque on tooth surfaces. 
Studies have demonstrated a higher gingival bleeding and plaque index in subjects with 
hyposalivation but without shown a correlation between salivary flow rate and gingival 
bleeding index or plaque index (73, 74).  
Few studies have managed to report an increased risk of periodontal disease in Sjögren’s 
syndrome (75-77). Ergun et al. had summarised the studies that evaluated the periodontal 
status of the patients with Sjögren’s syndrome (78) (Table 3).  
Number of the teeth (NT), bleeding on probing (BOP) (expressed as the % of sites which 
bled upon gentle probing), approximal plaque index (API) (expressed as the % of sites 
which presented plaque), probing pocket depth (PPD) were used in studies evaluating the 
periodontal status of patients with SS since they are easy to perform and produced adequate 
results for this kind of evaluation (78). Ergun et al. found out a significant difference 
between patients with SS and healthy controls in regard to API and BOP (78). This result is 
in agreement with the studies which have found that the API, PPD and BOP are 
significantly higher in SS patients than healthy subjects (75-77, 79). Other studies, however, 
have shown that SS patients are not at higher risk of having periodontitis (56, 79-83).  
It is well known that BOP is strongly corralated to API and both are correlated with tooth 
brushing efficiency (84). Ergun et al concluded that as there was no statistically significant 
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Author 
Study 
group(s) 
Control 
group(s) 
Difference 
inapproximal 
plaque ındex 
(API) 
Difference
in 
bleeding 
on probing 
(BOP) 
Difference 
in 
periodontal 
probing 
depth 
(PPD) 
Difference 
in 
attachment 
loss 
Difference in 
supragingiv
al calculus
Difference 
in 
subgingiva
l calculus
Difference
in alveolar 
bone loss
Difference
in GCF 
volume 
Difference 
in DMF-T 
Conclusion: 
Higher risk 
of having 
periodontitis
? 
Tseng 
(1991) 
SS 
(n=14) 
HS (n=14) NS NS NS NS NS NS - - S No 
Celenligil 
et al 
(1994) 
SS 
(n=17) 
HS (n=14) S S S - - - - - 
S 
(missing) 
Yes 
Najera  
et al 
(1997) 
SS-1 
(n=23) 
SS-2 
(n=2) 
HS (n=24) S NS NS S - - S - S Yes 
Ravald 
and List 
(1998) 
SS-1 
(n=22) 
HS (n=21) NS NS NS NS - - - - S (decay) No 
Pedersen 
et al 
(1999) 
SS-1 
(n=16) 
HS (n=13) NS NS NS - - - - - S No 
Boutsi  
et al 
(1999) 
SS-1 
(n=8) 
SS-2 
(n=16) 
Patients 
with other 
autoimmu
ne 
diseases 
(n=27) 
HS (n=29)
NS NS NS NS - - - - NS No 
Schiodt 
et al 
(2001) 
SS-1 
(n=57) 
 
HS (n=75) - NS NS - S NS - - - No 
Kuru  
et al 
(2002) 
SS-1 
(n=8) 
SS-2 
(n=10) 
HS (n=11) NS NS NS NS - - - - - No 
Jorkjend 
et al 
(2003) 
SS-2 
(n=33) 
HS (n=33) - - - 
S (mandi-
bular 
teeth) 
- - - - 
S (teeth) 
NS 
(fillings) 
No 
Leung  
et al 
(2004) 
SS-1 
(n=26) 
SS-2 
(n=25) 
HS (n=29) - - - - - - - - S - 
Rhodus 
et al 
(2005) 
SS-1 
(n=10) 
HS (n=10) S NS NS S - - - S - 
No (but 
more 
gingival 
recession) 
Pers et al 
(2005) 
SS-1 
(n=9) 
Patients 
with 
xerostomia
(n=15) and 
with 
periodontal
disease 
(n=10) 
NS NS NS - - - - - NS - 
Marton 
et al 
(2006) 
 
SS-1 
(n=38) 
 
HS (n=34) - S S - - - - - S Yes 
Table 3. Studies which evaluated the periodontal status of the patients with Sjögren’s 
syndrome (GCF: gingival creviculer fluid, DMF-T: decayed, missing, and filled permanent 
teeth, HS: healthy subjects, S: statistical significant; NS: not statistical significant) (78). 
difference between patients with SS and healthy controls regarding to their tooth brushing 
habits (p>0.05) it can be concluded that the significant difference in terms of API could have 
been occurred due to the low SFR levels of the subjects participated in the study group 
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which is in agreement with Marton et al. (75, 78). Their results indicate that patients with SS 
carry a higher risk of having periodontitis. 
There is a limited number of the studies regarding evaluation of the periodontal status of 
the subgroups of SS patients in terms of plaque accumulation, gingival inflammation and 
pocket depth. Most of these studies did not find a statistically significant difference between 
primary and secondary SS patients in terms of their periodontal status (56, 75, 82, 83, 85, 86). 
Najera et al. (77) found a significant difference in plaque index, but they did not find a 
statistically significant difference in gingival bleeding and periodontal pocket depth 
between SS-1 and SS-2 patients. The lack of difference in periodontal status between SS-1 
and SS-2 subjects may indicate that both types of SS do not play significant role in 
periodontal status (66, 78, 80).  
2.3.2 Treatment 
As mentioned before, the treatment of SS is palliative and turns to the xerostomia related 
complications. One of these is the increased periodontal damage seen in patients with SS as 
accepted as some authors who found out possible correlations between the disease and the 
periodontal status of this type of patients. The aim is to maintain impeccable hygiene by 
having regular follow-ups, teaching oral hygiene instructions and some topical applications. 
The treatment should be conservative aiming to reduce the bacterial clearance in the oral 
cavity, as well as the accumulation of dental plaque on tooth surfaces. 
2.4 Oral mucosal lesions  
Oral health status of patients with SS has been investigated in many studies, previously (56, 
75, 87-91). Subjective xerostomia has been reported in higher percentages (75.18% to 91.84%) 
in the patients with SS (56, 75, 88, 91). Additional dryness-related signs in patients with SS 
are angular chelitis, redness of the tongue, atrophy of filiform papilae (Figure 3 and 4), 
erythematous buccal mucosa (Figure 5), hardpalate and softpalate, difficulties and pain on 
swallowing, burning syndrome, sensitivity to acid and/or spicy food, dysgeusia and bitter 
taste (8, 87-93). Most of the subjective symptoms such as dry mouth feeling and dysphagia 
have been reported to be in direct correlation with the decreased salivary flow rate which 
could also affect the sensory process of swallowing that leads to pain and difficulties on 
swallowing (73, 94).  
Ergun et al have shown that oral objective and subjective signs on oral clinical examination 
are very common among patients with SS regardless its type. Similarly, a recent study 
demonstrated that oral health related quality of life was poor in patients with SS (95). The 
reason why dysgeusia was a common subjective symptom of SS-2 when compared with that 
of SS-1, could be related to the use of D-penicillamine which has found as common drug-
therapy for patients with RA. Dysgeusia was reported to be seen as a frequent problem of 
patients using D-penicillamine (96). 
Ergun et al have shown that oral examination of the patients with SS revealed no statistically 
significant difference between SS-1 and SS-2 patients in regard to presence of angular 
stomatitis, oral ulcerations, atrophic, reddened and dry mucosa, dysgeusia and atrophy of 
filiform papilla (78). Similar percentage of the two subgroups of SS complained about  
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Fig. 3. Atrophy of filiform papillae 
 
Fig. 4. Redness of the tongue 
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Fig. 5. Erythematous buccal mucosa 
subjective xerostomia, burning sensation, pain on swallowing and hypersensitivity. They 
observed significant differences between patients with SS and healthy subjects in terms of 
the clinical oral findings associated with SS (Table 4).  
 
SS 
(n=37) 
N, %, 
HS 
(n=37) 
N, %, 
p 
Angular Chelitis 8 (21.62%) 0 (0%) 0.005 (S) 
Oral Ulcerations 13 (35.13%) 0 (0%) 0.0001 (S) 
Atrophic  
Mucosa 
28 (75.67%) 3 (8.10%) 0.0001 (S) 
Dry Mucosa 23 (62.16%) 1 (2.70%) 0.0001 (S) 
Reddened  
Mucosa 
23 (62.16%) 5 (13.51%) 0.0001 (S) 
Atrophy of  
Filiform Papilla 
18 (48.65%) 4 (10.81%) 0.001 (S) 
Xerostomia 32 (86.49%) 5 (13.51%) 0.0001 (S) 
Burning Sensation 29 (78.38%) 5 (13.51%) 0.0001 (S) 
Pain on Swallowing 23 (62.16%) 4 (10.81%) 0.0001 (S) 
Dysgeusia 30 (81.08%) 3 (8.10%) 0.0001 (S) 
Hypersensitivity 22 (59.46%) 0 (0%) 0.0001 (S) 
Table 4. Positive objective and subjective signs on oral clinical examination of the patients 
with SS (78) 
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2.5 Oral flora & treatment 
2.5.1 Oral flora 
A continuous flow of saliva is important in preventing oral colonization by Candida, as the 
constant flushing action of saliva may remove the unattached or loosely attached Candida 
from the oral cavity (86). It has been shown that high Candida albicans counts in saliva are 
associated with clinical signs of candidiasis (97). Also there has also been shown an inverse 
association between salivary flow rate and C. albicans counts in saliva (98-100). Various 
investigators have reported a high prevalence of oral Candida species in patients with SS 
when compared with those of healthy controls (90, 101-104), while others have found that 
there is no significant difference between patients with SS and healthy controls in terms of 
presence of candidiasis (86, 101). Most reports indicate that C. albicans is the predominant 
yeast isolated in gingival crevicular fluid and in periodontal pockets of the periodontal 
patients as well as in healthy subjects, although Candida glabrata and Candida tropicalis have 
also been found, albeit infrequently (33, 86, 100, 102, 104). Additionally, one study showed 
that C. albicans was detected in gingival crevicular fluid at one measurement site in one of 
the SS-1 subjects but not in the control group (79). 
Saliva has antibacterial, remineralizing, digestive, soft tissue reparative, lubricative, 
buffering, and cleansing properties. Therefore, decreased saliva production, which occurs in 
SS, can directly contribute to the oral and dental complications experienced by these 
patients. An inverse relationship between salivary flow rates and the level of Candida 
infection has been described, previously (86). Additionally, infection by C. albicans has been 
reported more frequently in individuals with SS than in the general population (87). While 
an even higher proportion of the total population (up to 60%) carry C. albicans in their 
mouths without clinical symptoms. The amount of the candidal load is important for 
development of candidiasis (105). As the quantification is essential for candidal assessment, 
we have detected the salivary Candida levels of the study population. Ergun et al have found 
out that Candida counts in saliva were statistically higher either in SS-1 or SS-2 patients as 
compared with that of the healthy control, which is in agreement with the results of other 
similar studies (78, 89, 99). 
For successful colonization and infection, adhesion to oral surfaces is necessity. C. albicans 
can adhere to epithelial cells of buccal mucosa, the tongue, tooth surfaces, various oral 
prostheses such as dentures, and other oral micro-organisms that have already colonized 
these surfaces. Clinically, C. albicans can be cultured from swabs of the buccal mucosa, 
tongue, teeth, denture surfaces, and dental plaque samples. The flushing effect of saliva and 
anti-candidal salivary components such as lysozyme, histatins, lactoferrin, and calprotectin 
are the innate host defenses which act to remove or kill invading yeasts (106). The decreased 
salivary flow means the decreased host defense. Ergun et al. showed that candidal 
colonization on the buccal epithelial and the dorsal tongue was found to be in higher in SS 
patients than in healthy controls. In colonized individuals with no clinical symptoms of 
candidiasis, C. albicans is most frequently found on the dorsum of the tongue. Although 
Almståhl & Wikström (107) did not find an increase of frequency of Candida in subjects with 
hyposalivation, those authors did not analyse Candida colonization on the tongue’s dorsal 
surface, which is the main ecological niche for Candida in the oral cavity.  
www.intechopen.com
 
Oral Aspects of Sjögren’s Syndrome 
 
163 
Denture wearing is one of the major predisposing factor in humans for oral candidiasis. In 
denture wearers, the fitting surface of the denture is the main reservoir of the yeasts (108). 
Angular chelitis is commonly associated with denture-induced stomatitis. Ergun et al. 
stressed that no statistically significant difference was found between SS and healthy 
subjects on the prevalence of C. albicans colonization on dentures, palatinal and angular 
areas who use dentures with similar cleaning habits. Absence of normal salivary flow 
results with candidal colonization on the denture surfaces, palatinal mucosa and angular 
area in denture wearers even with normal or decreased salivary flow rate.  
As there is limited findings in healthy subjects, yeasts especially C. albicans have been 
recovered from periodontal pockets of patients with chronic periodontitis in different rates 
(7.1-19.6%) (104, 109-112). Brill considered gigngival crevicular fluid a transudate, a passage 
of fluid from bloodstream (113). But it’s also known that amount of gigngival crevicular 
fluid increases with periodontal disease and decreases during health (114). According to 
Cimasoni, gigngival crevicular fluid flow rate in slightly inflamed gingiva is about 0.1mg in 
3 minutes, which leads us to think that gigngival crevicular fluid renews itself continuously 
(115). Ergun et al concluded that population it is found that the subjects showed slight to 
moderate signs of inflammation (78). Finding only one subject (2.70%) in each group who 
has C. albicans colonization in the gigngival crevicular fluid, might be because of this 
continuous flow despite high scores of positive candida albicans colonization in different 
areas of the mouth. Rhodus and Michalowicz (25) found almost the same result in their pilot 
study, in which they compared the periodontal status and prevalence of sulcular C. albicans 
between subjects with SS-1 and healthy control subjects. 
Ergun et al have found out that there were direct correlations between positive candida 
albicans colonization on buccal area and dry mucosa, hypersensitivity and pain on 
swallowing with no spesific reason (78). Additionally, they have shown a weak correlation 
between Candida carriage in saliva and pain on swallowing (78). Volter et al. and Logemann 
et al. reported that xerestomia affects the sensory process of swallowing (94, 116). It is well 
known that positive Candida carriage in saliva is mostly the result of the lower levels of 
salivary flow rate. From this available evidence, it can be assumed that difficulties and pain 
on swallowing could occur due to positive Candida carriage in saliva. But more studies with 
higher number of patients with SS are needed to confirm or refute this association. 
2.5.2 Treatment 
Reduced saliva predisposes patients to an overgrowth of Candida albicans (43). This may be 
augmented by the use of dentures, smoking and diabetes (43, 51). Recurrent oral candidiasis 
can be treated with topical anti-fungal medications. Oral rinses with anti-fungal medications 
such as nystatin and fluconazole are effective in the treatment of oral candidiasis and for 
relieving oraldiscomfort (43, 117, 118). Management of chronic erythematous candidiasis 
and angle cheilitis can be based on the prescription of nystatin in tablets or solution (100,000 
IU 4-6 times a day), or miconazole gel 4 times a day (119). Removable dental prostheses 
should be treated separated by soaking in anti-fungal medication. Angular cheilitis can be 
treated with nystatin ointment or clotrimazole cream. Milillo et al. recently reported that 5% 
amorolfine anti-fungal varnish was effective for Candida-related denture stomatitis (120).  
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As mentioned before dentures may not be suitable for patients SS; however, dentures could 
be the only restorative choice (43). The tongue adheres to and dislodges the denture, causing 
decreased retention of partial and totally removable prosthesis and resulting in abrasions, 
sore spots, ulceration and irritation, all unpleasant and painful experiences for the patient (4, 
43). Despite this, an implant-supported denture may be successful; however, the high cost of 
this denture could represent a problem for patients. If dryness is a continuous problem, the 
manufacture of dentures with reservoirs or chambers for artificial saliva is suggested for 
continuous delivery of saliva, although these dentures should not be worn during eating 
(43, 121-123).  
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